Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives

Area of Science:

• Medicinal Chemistry
• Virology
• Pharmacology

Background:

• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are crucial in HIV-1 treatment alongside NRTIs and PIs.
• NNRTIs are categorized into first-generation (random screening) and second-generation (comprehensive strategies).
• Second-generation NNRTIs offer advantages like antiviral potency, specificity, and low toxicity.

Purpose of the Study:

• To review the development and recent advancements in second-generation NNRTIs for HIV-1 treatment.
• To highlight key findings and published results concerning second-generation NNRTIs.
• To provide guidelines for the development of next-generation NNRTIs.

Main Methods:

• Review of scientific literature focusing on first and second-generation NNRTIs.
• Analysis of drug development strategies including molecular modelling and rationale-based synthesis.
• Evaluation of biological and pharmacokinetic data for NNRTIs.

Main Results:

• Second-generation NNRTIs demonstrate broad-spectrum activity and overcome resistance associated with first-generation drugs.
• Advanced development strategies have led to NNRTIs with enhanced antiviral efficacy and safety profiles.
• Significant progress has been made in understanding the structure-activity relationships of NNRTIs.

Conclusions:

• Second-generation NNRTIs represent a significant advancement in HIV-1 therapy.
• Continued research into NNRTIs is essential for combating drug resistance and improving patient outcomes.
• Future NNRTIs development should focus on further enhancing potency and overcoming emerging resistance mechanisms.